Business Context and Reporting Period
Company: Bausch Health Companies Inc.
Filing Type: Form 8-K (Current Report)
Date: March 19, 2025
Event: Announcement of a major capital restructuring involving a new debt offering and the redemption of existing notes.
Key Financial Metrics and Capital Structure
This filing details a refinancing transaction rather than operational financial results. Key capital metrics include:
- New Senior Secured Notes: $4.0 billion aggregate principal amount due 2032.
- New Term Loan Facility: $3.4 billion, 5.5-year secured term loan B facility.
- New Revolving Facility: At least $400 million, five-year senior secured revolving credit facility.
- Existing Debt to be Retired: Includes 5.500% Senior Secured Notes due 2025, 9.000% Senior Notes due 2025, 6.125% Senior Secured Notes due 2027, 5.750% Senior Secured Notes due 2027, and 9.000% Senior Secured Notes due 2028 (HoldCo Notes).
Note: The filing does not provide current revenue, profit, cash flow, or margin data.
Material Changes and Transaction Details
The Company is executing a comprehensive debt refinancing to extend maturities and restructure its capital base. Material changes include:
- Debt Extension: Replacement of maturing 2025 and 2027 debt with new notes due 2032 and a new term loan.
- Redemption Notices: Conditional redemption notices were delivered for all "Existing Notes."
- Redemption Dates:
- 2025 Notes: April 18, 2025.
- 2027 Notes and HoldCo Notes: April 4, 2025.
- Use of Proceeds: Net proceeds from the new Notes and Term Loan will repay the existing 2027 term loan, redeem the 2025 and 2027 notes, fund the redemption of HoldCo Notes, pay fees, and cover general corporate purposes.
Outlook, Risks, and Contingencies
Conditions Precedent: The redemption of existing notes is strictly conditioned upon the successful consummation of the new Notes offering and the funding of the New Term Loan Facility on or before the respective redemption dates.
Risks:
- Transaction Failure: There can be no assurance that conditions precedent will be satisfied or that the redemption will occur.
- Delay: The Company reserves the right to delay redemption dates in its sole discretion if conditions are not met.
- Regulatory Status: The new Notes are not registered under the Securities Act and are offered only to qualified institutional investors (Rule 144A) and non-U.S. persons (Regulation S).
Investor Verification Checklist
- Verify the final pricing and interest rates of the $4.0 billion 2032 Notes and the $3.4 billion Term Loan.
- Confirm the successful closing of the new credit facilities by the April 4 and April 18, 2025 redemption deadlines.
- Review the specific redemption premiums and accrued interest costs associated with retiring the 2025 and 2027 notes.
- Monitor for any announcements regarding the failure of conditions precedent, which could result in the existing notes remaining outstanding.